Raymond James Financial’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-5,758
Closed -$222K – 5549
2026
Q2
$222K Sell
5,758
-2,499
-30% -$76.1K ﹤0.01% 4997
2026
Q1
$205K Buy
+8,257
New +$214K ﹤0.01% 4876
2025
Q3
– Sell
-300
Closed -$4.8K – 5807
2025
Q2
$4.8K Sell
300
-59,374
-99% -$898K ﹤0.01% 6184
2025
Q1
$1.02M Buy
59,674
+39,292
+193% +$822K ﹤0.01% 3474
2024
Q4
$505K Hold
20,382
– – ﹤0.01% 3901

Other funds holding IMVT

Raymond James Financial's IMVT Position: Q3 2026 in Review

Raymond James Financial sold out of Immunovant (IMVT) in Q3 2026, closing a stake of 5,758 shares — an estimated $222K sold.

Raymond James Financial first reported a position in IMVT in Q4 2024 and held it in 5 quarters. The position peaked at $1.02M in Q1 2025. 232 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Raymond James Financial reported no remaining Immunovant position as of Q3 2026 after selling out during the quarter.
  • Raymond James Financial sold 5,758 Immunovant shares in Q3 2026, an estimated $222K.
  • Raymond James Financial first reported a position in Immunovant in Q4 2024 and held it in 5 quarters.
  • Raymond James Financial's Immunovant position peaked at $1.02M in Q1 2025.
  • 232 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.